Jagsonpal Pharmaceuticals Limited

NSEI:JAGSNPHARM Rapport sur les actions

Capitalisation boursière : ₹10.0b

La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !

Jagsonpal Pharmaceuticals Bilan de santé

Santé financière contrôle des critères 5/6

Jagsonpal Pharmaceuticals possède un total de capitaux propres de ₹1.9B et une dette totale de ₹89.4M, ce qui porte son ratio d'endettement à 4.8%. Son actif total et son passif total sont ₹2.2B et de ₹296.8M. L'EBIT de Jagsonpal Pharmaceuticals est ₹223.3M ce qui fait que son ratio de couverture des intérêts 25.4. Elle dispose de liquidités et de placements à court terme de ₹1.5B.

Informations clés

4.8%

Ratio d'endettement

₹89.41m

Dette

Ratio de couverture des intérêts25.4x
Argent liquide₹1.48b
Fonds propres₹1.87b
Total du passif₹296.76m
Total des actifs₹2.17b

Mises à jour récentes de la santé financière

Pas de mise à jour

Recent updates

There May Be Some Bright Spots In Jagsonpal Pharmaceuticals' (NSE:JAGSNPHARM) Earnings

May 27
There May Be Some Bright Spots In Jagsonpal Pharmaceuticals' (NSE:JAGSNPHARM) Earnings

There's Reason For Concern Over Jagsonpal Pharmaceuticals Limited's (NSE:JAGSNPHARM) Massive 27% Price Jump

Apr 30
There's Reason For Concern Over Jagsonpal Pharmaceuticals Limited's (NSE:JAGSNPHARM) Massive 27% Price Jump

A Look At The Fair Value Of Jagsonpal Pharmaceuticals Limited (NSE:JAGSNPHARM)

Apr 05
A Look At The Fair Value Of Jagsonpal Pharmaceuticals Limited (NSE:JAGSNPHARM)

Investor Optimism Abounds Jagsonpal Pharmaceuticals Limited (NSE:JAGSNPHARM) But Growth Is Lacking

Feb 06
Investor Optimism Abounds Jagsonpal Pharmaceuticals Limited (NSE:JAGSNPHARM) But Growth Is Lacking

Estimating The Intrinsic Value Of Jagsonpal Pharmaceuticals Limited (NSE:JAGSNPHARM)

Jul 29
Estimating The Intrinsic Value Of Jagsonpal Pharmaceuticals Limited (NSE:JAGSNPHARM)

A Look At The Intrinsic Value Of Jagsonpal Pharmaceuticals Limited (NSE:JAGSNPHARM)

May 13
A Look At The Intrinsic Value Of Jagsonpal Pharmaceuticals Limited (NSE:JAGSNPHARM)

Does Jagsonpal Pharmaceuticals (NSE:JAGSNPHARM) Deserve A Spot On Your Watchlist?

Jul 05
Does Jagsonpal Pharmaceuticals (NSE:JAGSNPHARM) Deserve A Spot On Your Watchlist?

A Look At The Fair Value Of Jagsonpal Pharmaceuticals Limited (NSE:JAGSNPHARM)

Jun 13
A Look At The Fair Value Of Jagsonpal Pharmaceuticals Limited (NSE:JAGSNPHARM)

Jagsonpal Pharmaceuticals Limited's (NSE:JAGSNPHARM) 0.6% Dividend Yield Looks Pretty Interesting

Apr 19
Jagsonpal Pharmaceuticals Limited's (NSE:JAGSNPHARM) 0.6% Dividend Yield Looks Pretty Interesting

Should You Be Adding Jagsonpal Pharmaceuticals (NSE:JAGSNPHARM) To Your Watchlist Today?

Mar 21
Should You Be Adding Jagsonpal Pharmaceuticals (NSE:JAGSNPHARM) To Your Watchlist Today?

Jagsonpal Pharmaceuticals Limited's (NSE:JAGSNPHARM) Stock Is Going Strong: Have Financials A Role To Play?

Feb 08
Jagsonpal Pharmaceuticals Limited's (NSE:JAGSNPHARM) Stock Is Going Strong: Have Financials A Role To Play?

The Attractive Combination That Could Earn Jagsonpal Pharmaceuticals Limited (NSE:JAGSNPHARM) A Place In Your Dividend Portfolio

Jan 08
The Attractive Combination That Could Earn Jagsonpal Pharmaceuticals Limited (NSE:JAGSNPHARM) A Place In Your Dividend Portfolio

Here's Why I Think Jagsonpal Pharmaceuticals (NSE:JAGSNPHARM) Is An Interesting Stock

Dec 21
Here's Why I Think Jagsonpal Pharmaceuticals (NSE:JAGSNPHARM) Is An Interesting Stock

Are Jagsonpal Pharmaceuticals's (NSE:JAGSNPHARM) Statutory Earnings A Good Reflection Of Its Earnings Potential?

Nov 30
Are Jagsonpal Pharmaceuticals's (NSE:JAGSNPHARM) Statutory Earnings A Good Reflection Of Its Earnings Potential?

Analyse de la situation financière

Passif à court terme: Les actifs à court terme de JAGSNPHARM ( ₹2.0B ) dépassent ses passifs à court terme ( ₹191.3M ).

Passif à long terme: Les actifs à court terme de JAGSNPHARM ( ₹2.0B ) dépassent ses passifs à long terme ( ₹105.5M ).


Historique et analyse du ratio d'endettement

Niveau d'endettement: JAGSNPHARM dispose de plus de liquidités que de sa dette totale.

Réduire la dette: Le ratio d'endettement de JAGSNPHARM est passé de 3.6% à 4.8% au cours des 5 dernières années.

Couverture de la dette: La dette de JAGSNPHARM est bien couverte par le flux de trésorerie opérationnel ( 393.3% ).

Couverture des intérêts: Les paiements d'intérêts de JAGSNPHARM sur sa dette sont bien couverts par l'EBIT ( 25.4 x couverture).


Bilan


Découvrir des entreprises saines